Adjuvanted-influenza vaccination in patients infected with HIV: a systematic review and meta-analysis of immunogenicity and safety

Chen, Yongchao; Zhou, Jiahao; Tian, Jiaming; Li, Bai-Hui; Liu, Lihui; Wei, Ke

doi:10.1080/21645515.2019.1672492

Cited by 3 publications

(4 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings taken together reiterate the importance of vaccine prevention for people with HIV infection, especially against influenza, SARS-CoV-2 and pneumococcus. Influenza vaccination is notoriously safe and is associated with acceptable levels of immunogenicity among patients with HIV infection [ 19 , 20 ]. However, in Romania, vaccination rates among this patient population remain generally low, and influenza-related hospitalizations and deaths among patients with HIV infection are reported annually [ 21 , 22 ].…”

Section: Discussionmentioning

confidence: 99%

Hospitalizations for Acute Otitis and Sinusitis in Patients Living with HIV: A Retrospective Analysis of a Tertiary Center in Romania

Pleșca,

Miron,

Marinescu

et al. 2024

JCM

View full text Add to dashboard Cite

Background/Objectives: Acute or chronic ear, nose and throat (ENT) conditions in people living with HIV can lead to hospitalization and affect their quality of life. The aim of our study was to determine the frequency and characteristics of hospitalizations for acute sinusitis (AS) and acute otitis (AO) in people living with HIV. Methods: We performed a retrospective analysis over the course of six years (from January 2018 to December 2023), assessing all hospitalizations for AS and/or AO occurring in patients living with HIV, at the largest infectious diseases hospital in Romania. Results: We identified a total of 179 cases, among which 149 cases (83.2%) were attributed to AS and 41 cases (22.9%) were due to AO. Among cases of AS, maxillary sinuses were most frequently involved (n = 140/149, 94.0%), and among cases of AO, acute congestive otitis media (n = 14, 34.1%) and acute purulent otitis media (n = 13, 31.7%) were the most common forms. The underlying HIV infection was classified as stage C3 in 57.5% of cases. In 19.6% of cases, it was possible to identify either the trigger or the etiological agent, and the most frequent bacterial pathogens were Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae and Pseudomonas aeruginosa. Conclusions: In conclusion, this study highlights that hospitalizations due to acute sinus and ear involvement are not isolated events in people living with HIV. A prospective follow-up is needed to gain a deeper and more dynamic understanding of how ENT health is affected in people with HIV infection. Furthermore, promoting prevention through vaccination may reduce to a certain extent the burden of ENT infections in this population.

show abstract

Section: Discussionmentioning

confidence: 99%

Hospitalizations for Acute Otitis and Sinusitis in Patients Living with HIV: A Retrospective Analysis of a Tertiary Center in Romania

Pleșca,

Miron,

Marinescu

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…40 Although the incidence of adverse reactions in the mRNA vaccine group was higher compared with that in the inactivated vaccine group, the majority of reported adverse events were mild and temporary, and did not generally lead to severe problems, indicating that the safety of COVID-19 vaccines in PLWH is acceptable as other administered vaccines in PLWH, including influenza vaccines, HPV vaccines and HBV vaccines. [41][42][43] Of note, a long-term surveillance of mRNA vaccines should be performed, especially in the PLWH population.…”

Section: Discussionmentioning

confidence: 99%

“…So far, the mechanism of adverse reactions caused by mRNA vaccine modality is still under investigation, and it may be associated with excessive activation of the complement system or non–IgE-mediated mast cells related to the lipid nanoparticle component of mRNA vaccine modality 40 . Although the incidence of adverse reactions in the mRNA vaccine group was higher compared with that in the inactivated vaccine group, the majority of reported adverse events were mild and temporary, and did not generally lead to severe problems, indicating that the safety of COVID-19 vaccines in PLWH is acceptable as other administered vaccines in PLWH, including influenza vaccines, HPV vaccines and HBV vaccines 41–43 . Of note, a long-term surveillance of mRNA vaccines should be performed, especially in the PLWH population.…”

Section: Discussionmentioning

confidence: 99%

Safety and Immunogenicity of SARS-CoV-2 Vaccines in People Living With HIV (PLWH): A Systematic Review and Meta-analysis of Real-World Studies

Fan,

Zhao,

et al. 2023

Infect Microb Dis

View full text Add to dashboard Cite

The safety and immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in people living with HIV (PLWH) in real world studies remain controversial. Thus, we conducted a comprehensive systematic review and meta-analysis to address this issue. Data search were conducted from PubMed, Web of science, and Embase. Adverse events following vaccination, the risk ratio (RR) of SARS-CoV-2-specific IgG seroconversion, and the level of anti-SARS-CoV-2 neutralizing antibodies were compared between the PLWH group and a healthy control group. A total of 10,582 PLWH from 22 studies were included. In our analysis, the incidence of local or systemic adverse events after the first SARS-CoV-2 vaccine dose was not statistically different between PLWH and healthy controls. However, there was a statistical difference after the second dose (RR = 0.83, 95% CI: 0.71 – 0.98). The seroconversion rate of SARS-CoV-2 IgG antibodies in PLWH was significantly lower than that in the healthy control group (RR = 0.94, 95% CI: 0.89-0.98; I2 = 80%, P < 0.01). The anti-SARS-CoV-2 neutralizing antibody titers in PLWH after full immunization were also significantly lower than that in the healthy control group (RR = 0.91, 95% CI: 0.85-0.98; I2 = 81%, P < 0.01). The safety and tolerance of COVID-19 vaccines in PLWH are acceptable. However, their immunogenicity may be impaired to a certain extent, characterized by a lower IgG seroconversion rate and neutralizing antibody titers compared with healthy individuals. These findings should provide guidance for optimizing future COVID-19 vaccination strategies among PLWH.

show abstract

“…22 Nevertheless, the vaccination rate of influenza booster in PLWH is low 22 because of concerns about vaccine efficacy and adverse effects and misconceptions about influenza disease. 23 One published meta-analysis has evaluated the immunogenicity and safety of adjuvant influenza vaccination in PLWH, 24 and a relevant analysis of two-dose influenza vaccine is still lacking. We conducted a meta-analysis to compare the immunogenicity (seroprotection rate, seroconversion rate, GMT) and safety of booster doses in PLWH.…”

Section: Introductionmentioning

confidence: 99%

A meta-analysis of immunogenicity and safety of two versus single-doses of influenza A (H1N1) vaccine in person living with HIV

Zhang,

Geng,

et al. 2023

Int J STD AIDS

View full text Add to dashboard Cite

Purpose: Influenza vaccination of person living with HIV (PLWH) is a powerful means to tackle severe clinical outcomes. Few data on two doses of influenza vaccine in PLWH are available. Research Design: To evaluate the immunogenicity and safety of two doses of vaccine as compared with single dose in PLWH, we searched Pubmed, Embase, and web of science databases for relevant articles (January 2009 to April 2023). Pooled SMD or RR and 95% CI were calculated. Results: A total of 2436 participants from 14 studies were included. Compared to single dose influenza vaccine regimen, the pooled RR of seroprotection and seroconversion for two doses of vaccines was 1.14 (95%CI: 1.08–1.21) and 1.25 (95%CI: 1.16–1.34), respectively; the SMD of GMT was 0.42 (95%CI: 0.35, 0.49). Regarding safety, the fever risk in PLWH receiving two doses of vaccine was 3.42 fold higher than that of single dose vaccine, and the risk of myalgia had a quarter reduction. No serious vaccine-related adverse events were reported. Conclusions: Collectively, two doses of the vaccine are associated with a better immunogenicity and an acceptable safety in PLWH. Two doses of the adjuvant vaccination might be a superior vaccination regimen.nation regimen.

show abstract

Adjuvanted-influenza vaccination in patients infected with HIV: a systematic review and meta-analysis of immunogenicity and safety

Cited by 3 publications

References 46 publications

Hospitalizations for Acute Otitis and Sinusitis in Patients Living with HIV: A Retrospective Analysis of a Tertiary Center in Romania

Hospitalizations for Acute Otitis and Sinusitis in Patients Living with HIV: A Retrospective Analysis of a Tertiary Center in Romania

Safety and Immunogenicity of SARS-CoV-2 Vaccines in People Living With HIV (PLWH): A Systematic Review and Meta-analysis of Real-World Studies

A meta-analysis of immunogenicity and safety of two versus single-doses of influenza A (H1N1) vaccine in person living with HIV

Contact Info

Product

Resources

About